Eurofins Viracor: All Resources

This interesting presentation will review The University of Nebraska's Kidney Transplant program's strategy of using CMV inSIGHT T Cell Immunity testing to serially monitor high risk kidney transplant patients to evaluate if prophylaxis could be discontinued early. Dr. Clifford Miles will review data originally presented at the Cutting Edge of Transplantation earlier this year. Dr. Miles is the Medical Director of Kidney and Pancreas Transplant at the University of Nebraska's Medical Center and Associate Professor, Nephrology Division at UNMC's college of medicine. 

Join us for an insightful presentation with real-world data and patient case studies utilizing the CMV inSIGHT™ T Cell Immunity test. Identify how you can utilize this cell mediated immunity assay in your immunocompromised patients to evaluate their immune response to CMV. These answers can assist in personalizing your approach to your patients CMV antiviral therapy.

Learn how nephrologists, Dr. Garuav Gupta and Dr. Adnan Khan, utilize inSIGHT testing in Kidney transplant patients. During this excerpt of the panel discussion, speakers present case studies of their utilization of diagnostics to improve patient outcomes in challenging and complicated contexts. They will discuss practical uses of the inSIGHT™ T cell immunity assay, including their application in managing post-transplant patient care.

In this episode of the Eurofins Viracor podcast listen to our Transplant Radio interview series part 1 from ATC 2022 in Boston. We exhibited as Eurofins Transplant, which is comprised of Eurofins Viracor, Eurofins Transplant Genomics, Eurofins Donor & Product Testing (DPT), Eurofins Ascend Clinical and Eurofins CellTx.

In this episode of the Eurofins Viracor podcast listen to our Transplant Radio interview series part 2 from ATC 2022 in Boston. We exhibited as Eurofins Transplant, which is comprised of Eurofins Viracor, Eurofins Transplant Genomics, Eurofins Donor & Product Testing (DPT), Eurofins Ascend Clinical and Eurofins CellTx.

In this episode of the Eurofins Viracor podcast listen to our Transplant Radio interview series part 3 from ATC 2022 in Boston. We exhibited as Eurofins Transplant, which is comprised of Eurofins Viracor, Eurofins Transplant Genomics, Eurofins Donor & Product Testing (DPT), Eurofins Ascend Clinical and Eurofins CellTx.

Join Dr. Chemaly and his team at MD Anderson as they explore CMV T Cell Immunity testing to identify high-risk cellular therapy recipients for clinically significant CMV infection. Learn about early treatment benefits for low-level CMV viremia and the test's role in managing CMV across risk groups. Includes a Q&A session—don't miss this insightful discussion!

In this webinar, Drs. Raval, Khawaja, and Kleiboeker discuss advancements in virus-specific T-cell immunity, focusing on CMV and SARS-CoV-2. Dr. Raval shares insights on using CMV T Cell Immunity panels in heart transplant patients, Dr. Khawaja covers CMV cellular immunity in hematopoietic cell transplant recipients, and Dr. Kleiboeker introduces the SARS-CoV-2 inSIGHT T Cell Immunity test and future innovations in T cell immunity testing.

In this episode we feature a recent White Paper and our CMV T Cell immunity panel. (See the featured resource following. This episode discusses CMV cell mediated immunity and the recently released white paper evaluating various methodologies, including Eurofins Viracor’s CMV T Cell Immunity Panel.